Prometheus Biosciences Inc (RXDX)

Currency in USD
199.92
0.00(0.00%)
Closed·
Showing Prometheus Biosciences historical data. For real-time data please try another search
Day's Range
199.60199.98
52 wk Range
199.60199.98
Key Statistics
Prev. Close
199.92
Open
199.68
Day's Range
199.6-199.98
52 wk Range
199.6-199.98
Volume
-
Average Volume (3m)
1.58M
1-Year Change
0%
Book Value / Share
-
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock

Prometheus Biosciences Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy

Prometheus Biosciences Inc Company Profile

Prometheus Biosciences, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of novel therapeutics for the treatment of inflammatory bowel diseases (IBD). Its lead product includes PRA023, a humanized IgG1 monoclonal antibody (mAb), which is in a Phase IIa clinical trial for the treatment of ulcerative colitis and Crohn’s disease, as well as systemic sclerosis-associated interstitial lung disease. The company also develops PR300, a G-protein-coupled receptor modulator for IBD and potentially other immune-mediated diseases; PRA052, an anti-CD30L mAb for IBD; PR1100, an anti-cytokine receptor mAb for IBD and other immune-mediated diseases; and PR2100, an anti-inflammatory cytokine mAb for IBD and inflammatory and fibrotic diseases. Prometheus Biosciences, Inc. was formerly known as Precision IBD, Inc. and changed its name to Prometheus Biosciences, Inc. in October 2019. The company was founded in 1995 and is based in San Diego, California. As of June 16, 2023, Prometheus Biosciences, Inc. operates as a subsidiary of Merck & Co., Inc.

Earnings

Latest Release
Nov 09, 2023
EPS / Forecast
-- / -0.9833
Revenue / Forecast
-- / 150.00K
EPS Revisions
Last 90 days

RXDX Income Statement

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.